Krensavage Asset Management LLC decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 16.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 178,358 shares of the medical research company’s stock after selling 34,297 shares during the quarter. Amgen makes up 11.7% of Krensavage Asset Management LLC’s holdings, making the stock its 4th largest holding. Krensavage Asset Management LLC’s holdings in Amgen were worth $34,721,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Ruggie Capital Group boosted its position in Amgen by 297.1% during the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares in the last quarter. Arlington Partners LLC boosted its position in Amgen by 86.7% during the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 65 shares in the last quarter. Massey Quick Simon & CO. LLC boosted its position in Amgen by 710.5% during the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Next Capital Management LLC bought a new stake in Amgen during the fourth quarter valued at about $33,000. Finally, Essex Investment Management Co. LLC bought a new stake in Amgen during the fourth quarter valued at about $39,000. 79.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of AMGN stock opened at $177.47 on Monday. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57. The company has a market cap of $109.31 billion, a P/E ratio of 12.32, a P/E/G ratio of 2.17 and a beta of 1.21. Amgen, Inc. has a twelve month low of $165.22 and a twelve month high of $210.19.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.27%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 40.28%.
AMGN has been the topic of a number of recent research reports. BMO Capital Markets initiated coverage on Amgen in a research report on Thursday, March 14th. They set an “outperform” rating and a $228.00 price objective on the stock. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $190.00 price target on shares of Amgen in a report on Wednesday, January 30th. Leerink Swann lowered their price target on Amgen from $200.00 to $192.00 and set a “market perform” rating for the company in a report on Wednesday, January 30th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Finally, Citigroup raised their price target on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a report on Friday, January 4th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Amgen currently has an average rating of “Hold” and a consensus target price of $209.11.
In related news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $190.00, for a total transaction of $380,000.00. Following the completion of the transaction, the director now directly owns 14,988 shares in the company, valued at $2,847,720. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by company insiders.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Straddles
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.